Changes in Hong Kong stocks | Hengrui Pharmaceutical (01276) rose nearly 4%. The company bought back A-shares for the first time. Institutions are optimistic that the non-oncology sector will continue to contribute to product-side growth

The Zhitong Finance App learned that Hengrui Pharmaceutical (01276) rose nearly 4%. As of press release, it had risen 3.2% to HK$45.8, with a turnover of HK$595.373 million.

According to the news, Hengrui Pharmaceutical announced that it will spend 14.5036 million yuan to buy back 335,000 A-shares on September 17, 2026. According to the Zheshang Securities Research Report, 2026H1's innovative drug sales revenue was 8.809 billion yuan, an increase of 16.38% over the previous year, accounting for 63.16% of drug sales revenue. Among them, revenue from innovative non-oncology products was 2,545 billion yuan, an increase of 73.97% over the previous year, contributing about 87% of the revenue increase of innovative drugs. The increase was mainly due to hengagliptin and emaxitinib, funacizumab, and ricaximab newly included in medical insurance. The bank believes that with the gradual release of newly included medical insurance products, it is optimistic that the non-oncology sector will continue to contribute product-side growth.